Posts by: Alice Melão

News, PAH News

A new generic version of Actelion’s Tracleer (bosentan) developed by Teva Pharmaceutical was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension ... Read more

June 7, 2019June 7, 2019

Liquidia Moves Closer to Requesting FDA Approval of LIQ861 for PAH

News, PAH News

The latest INSPIRE Phase 3 trial data on LIQ861 as a treatment for pulmonary arterial hypertension (PAH) support the submission of a New Drug Application (NDA) with the U.S. ... Read more

April 1, 2019April 1, 2019

Increased Production of Nestin Protein Involved in PAH Development, Study Suggests

News, PAH News

Increased production of a protein called Nestin by cells lining the blood vessels in the lungs may contribute to the development and progression of pulmonary arterial hypertension (PAH), a ... Read more

March 20, 2019March 26, 2019

Opsumit Has Potential to Improve Right Ventricle Function in PAH Patients, Phase 4 Data Show

News, PAH News

Treatment with Opsumit (macitentan) can significantly improve the heart’s right ventricular function, reverse cardiac tissue remodeling, and reduce pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension (PAH), preliminary ... Read more

March 18, 2019March 26, 2019

Cell Therapies Show Potential as Treatment for PAH, Review Finds

News, PAH News

Regenerative cell therapy can induce significant improvements in key clinical features of pulmonary arterial hypertension (PAH) in animal models, a review study shows. The study’s findings suggest that such ... Read more

February 22, 2019February 28, 2019

Complexa Starts Dosing in Phase 2 Trial to Evaluate CXA-10 for PAH

News, PAH News

The first patient has been given the investigational therapy CXA-10 in an ongoing Phase 2 trial in patients with pulmonary arterial hypertension (PAH), Complexa, the product’s developer, announced. The ... Read more

February 15, 2019February 22, 2019

Pulmonary Artery Denervation Can Improve CpcPH Patients’ Outcome, Trial Shows

News

Invasive pulmonary artery denervation is safe and can improve the outcome of patients with combined pre- and post-capillary pulmonary hypertension associated with left heart failure, compared with standard of ... Read more

February 4, 2019February 7, 2019

Early Results on Rodatristat Ethyl Support Launch of Phase 2 Trial in PAH Patients

News, PAH News

Preclinical and early clinical data showing the safety and potential therapeutic activity of rodatristat ethyl support its progression into Phase 2 trials in patients with pulmonary arterial hypertension (PAH). ... Read more

February 1, 2019February 8, 2019

Neurological Problems Possible in Premature Babies with BPD-related PH, Study Finds

News, PH News

Pulmonary hypertension (PH) is associated with poorer neurodevelopmental outcome and impaired growth in the first two years of life for preterm infants with bronchopulmonary dysplasia, a study shows. The ... Read more

January 11, 2019January 14, 2019

Long-term Adempas Treatment May Reverse Right Heart Deficits in Patients with PAH, CTEPH, Study Finds

CTEPH News, News, PAH News

Long-term treatment with Adempas (riociguat) can reduce right heart size and improve the heart’s pumping function in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), ... Read more

Posts by: Alice Melão

Alice Melão

FDA Approves Generic Bosentan Tablets in US for PAH Treatment

Liquidia Moves Closer to Requesting FDA Approval of LIQ861 for PAH

Increased Production of Nestin Protein Involved in PAH Development, Study Suggests

Opsumit Has Potential to Improve Right Ventricle Function in PAH Patients, Phase 4 Data Show

Cell Therapies Show Potential as Treatment for PAH, Review Finds

Complexa Starts Dosing in Phase 2 Trial to Evaluate CXA-10 for PAH

Pulmonary Artery Denervation Can Improve CpcPH Patients’ Outcome, Trial Shows

Early Results on Rodatristat Ethyl Support Launch of Phase 2 Trial in PAH Patients

Neurological Problems Possible in Premature Babies with BPD-related PH, Study Finds

Long-term Adempas Treatment May Reverse Right Heart Deficits in Patients with PAH, CTEPH, Study Finds

Pin It on Pinterest